In today’s recent session, 0.39 million shares of the Xilio Therapeutics Inc (NASDAQ:XLO) have been traded, and its beta is -0.05. Most recently the company’s share price was $1.17, and it changed around $0.18 or 18.18% from the last close, which brings the market valuation of the company to $51.42M. XLO at last check was trading at a discount to its 52-week high of $2.89, offering almost -147.01% off that amount. The share price’s 52-week low was $0.49, which indicates that the recent value has risen by an impressive 58.12% since then. We note from Xilio Therapeutics Inc’s average daily trading volume that its 10-day average is 0.18 million shares, with the 3-month average coming to 154.43K.
Xilio Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended XLO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Xilio Therapeutics Inc is expected to report earnings per share of -0.25 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Instantly XLO has been showing a green trend so far today with a performance of 18.18% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.1600 on recent trading daydecreased the stock’s daily price by -0.86%. The company’s shares are currently up 112.73% year-to-date, but still up 36.05% over the last five days. On the other hand, Xilio Therapeutics Inc (NASDAQ:XLO) is 56.00% up in the 30-day period. We can see from the shorts that 0.1 million shares have been sold at a short interest cover period of 0.76 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 83.29% from its current value. Analyst projections state that XLO is forecast to be at a low of $7 and a high of $7.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Xilio Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 8.33 percent over the past six months and at a 54.68% annual growth rate that is well above the industry average of 17.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 59.00% in revenue this quarter, and will report an increase of 59.40% in the next quarter.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 3.3M in revenue for the current quarter. 2 analysts expect Xilio Therapeutics Inc to make 3.3M in revenue for the current ending quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.91%.
XLO Dividends
Xilio Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-09.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 40.93% of Xilio Therapeutics Inc shares, and 30.22% of them are in the hands of institutional investors. The stock currently has a share float of 51.17%. Xilio Therapeutics Inc stock is held by 35.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 13.5618% of the shares, which is about 3.79 million shares worth $3.59 million.
ROCK SPRINGS CAPITAL MANAGEMENT LP, with 10.7595% or 3.0 million shares worth $2.85 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
